Syngeneic Mouse Models

Investigate cancer drugs in an immunologically intact environment to better assess immune responses and immunotherapy efficacy.

On this page

Overview Results Resources Tumor bank Request a study

Overview

Syngeneic Tumor Models: A Rapid System for Preclinical Immune Oncology Testing

Syngeneic mouse models are optimal for preclinical testing of innovative immuno-oncology (IO) therapeutics within a fully functioning, intact immune system. Champions offers a collection of established syngeneic models with endogenous mouse therapeutic targets or genetically modified to express specific human genes.

A collection of models representing all relevant tumor indications

Fast turnaround times, compatible with a variety of endpoint analyses to fully characterize the therapeutic response and mechanism

Deep molecular characterization and response to Standard of Care data available

Results

Well-characterized Response to Checkpoint Inhibitors

Champions has a wide range of well-characterized syngeneic mouse models with responses to immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4.

This platform can be used to assess efficacy or benchmark therapeutic agents against or in combination with standard of care immune therapies in an intact murine immune system.

Additionally, these models can help you investigate your agent mechanism of action by measuring differences in immune cell population before and after treatment.

Tumor bank

Champions Syngeneic Tumor Models

Champion's syngeneic mouse models offer key advantages for cancer research by using mice with a fully functional immune system to study immune responses in a natural context. These models replicate human immune system reactions, preserve the tumor microenvironment, and provide accurate insights into tumor-immune interactions. Cost-effective, reproducible, and versatile, they are ideal for testing immuno-oncology therapies, a wide range of tumor types, and assessing both innate and adaptive immune responses.

Cost-effective, large-scale syngeneic studies across multiple cell lines, including MC38, CT26, LLC, 4T1, EMT6, B16F10, RENCA, A20, KLN205, and MyC-CaP with key mutation and clinical characteristics.

An ideal platform for evaluating both innate and adaptive immune responses crucial for understanding immunotherapy effectiveness.

Flexible and versatile, enabling the study of various tumor types and testing of novel immunotherapies and combination therapies.

Resources

Explore our resources

A Comparison of Syngeneic & Humanized Models in Oncology Research

Syngeneic mouse models are preclinical in vivo models used to evaluate therapeutic candidates in mice with intact immune system. Humanized mouse models support the engraftment of many functional components of the human immune system. This Quick Guide gives a comparison of the two models and weighs the advantages and challenges of these models for oncology research.

Get started

Get in touch

Fill out the form to learn more about using our Syngeneic Tumor Models for your preclinical studies.